InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
A549-Dual™ Cells | ARF1 prevents aberrant type I interferon induction by regulating STING activa... | 2023 | Nat Commun. | Hirschenberger M. et al. | DOI: 10.1038/s41467-023-42150-4 |
Jurkat-Raji PD-1/PD-L1 assay (Bio-IC™) | Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverse... | 2023 | Front Immunol. | Mabbitt J. et al. | DOI: 10.3389/fimmu.2023.1250559 |
PMA - Phorbol myristate acetate | Detection and functional resolution of soluble immune complexes by an FcγR re... | 2023 | EMBO Mol Med. | Chen H. et al. | DOI: 10.15252/emmm.202114182 |
Ionomycin | Detection and functional resolution of soluble immune complexes by an FcγR re... | 2023 | EMBO Mol Med. | Chen H. et al. | DOI: 10.15252/emmm.202114182 |
pFUSE-CHIg-hG1 | Imaging Immune Cells Using Fc Domain Probes in Mouse Cancer Xenograft Models. | 2022 | Cancers (Basel). | Bernhard W. et al. | DOI: 10.3390/cancers14020300 |
Human CD16 Jurkat Reporter Cells for ADCC (NFAT) | Infection pre-Ad26. COV2. S-vaccination primes greater class switching and re... | 2023 | NPJ Vaccines. | Krause R.G.E. et al. | DOI: 10.1038/s41541-023-00724-9 |
Human CD32 Jurkat Reporter Cells for ADCP (NFAT) | Pathogen-driven degradation of endogenous and therapeutic antibodies during s... | 2023 | Nat Commun. | Toledo A.G. et al. | DOI: 10.1038/s41467-023-42572-0 |
Human CD16 Jurkat Reporter Cells for ADCC (NFAT) | Pathogen-driven degradation of endogenous and therapeutic antibodies during s... | 2023 | Nat Commun. | Toledo A.G. et al. | DOI: 10.1038/s41467-023-42572-0 |
QUANTI-Luc™: Luciferase Detection Reagent | Pathogen-driven degradation of endogenous and therapeutic antibodies during s... | 2023 | Nat Commun. | Toledo A.G. et al. | DOI: 10.1038/s41467-023-42572-0 |
Human CD16 Jurkat Reporter Cells for ADCC (NFAT) | Oral immunization with rVSV bivalent vaccine elicits protective immune respon... | 2023 | Vaccines (Basel) | Ouyang M.J. et al. | DOI: 10.3390/vaccines11091404 |
QUANTI-Luc™: Luciferase Detection Reagent | Oral immunization with rVSV bivalent vaccine elicits protective immune respon... | 2023 | Vaccines (Basel) | Ouyang M.J. et al. | DOI: 10.3390/vaccines11091404 |
Human CD16 Jurkat Reporter Cells for ADCC (NFAT) | Despite delayed kinetics, people living with HIV achieve equivalent antibody ... | 2023 | Front Immunol. | Motsoeneng B.M. et al. | DOI: 10.3389/fimmu.2023.1231276 |
Jurkat Reporter Cells (NFAT) | Brain-restricted mTOR inhibition with binary pharmacology. | 2022 | Nature | Zhang Z. et al. | DOI: 10.1038/s41586-022-05213-y |
Zeocin® | Brain-restricted mTOR inhibition with binary pharmacology. | 2022 | Nature | Zhang Z. et al. | DOI: 10.1038/s41586-022-05213-y |
Normocin® - Antimicrobial Reagent | African swine fever virus B175L inhibits the type I interferon pathway by tar... | 2023 | J Virol. | Ranathunga L. et al. | DOI: 10.1128/jvi.00795-23 |
QUANTI-Luc™: Luciferase Detection Reagent | African swine fever virus B175L inhibits the type I interferon pathway by tar... | 2023 | J Virol. | Ranathunga L. et al. | DOI: 10.1128/jvi.00795-23 |
Blasticidin | African swine fever virus B175L inhibits the type I interferon pathway by tar... | 2023 | J Virol. | Ranathunga L. et al. | DOI: 10.1128/jvi.00795-23 |
Hygromycin B Gold | African swine fever virus B175L inhibits the type I interferon pathway by tar... | 2023 | J Virol. | Ranathunga L. et al. | DOI: 10.1128/jvi.00795-23 |
Puromycin | African swine fever virus B175L inhibits the type I interferon pathway by tar... | 2023 | J Virol. | Ranathunga L. et al. | DOI: 10.1128/jvi.00795-23 |
Zeocin® | African swine fever virus B175L inhibits the type I interferon pathway by tar... | 2023 | J Virol. | Ranathunga L. et al. | DOI: 10.1128/jvi.00795-23 |